Pipeline

Product Development Pipeline

TScan’s technology platform has the potential to uncover new targets in a variety of diseases, including cancer, autoimmunity, and infectious disease. TScan is initially focused on cancer, with programs in both liquid and solid tumors.

NAME
DISCOVERY
PRE-CLINICAL
IND-ENABLING
CLINICAL

Liquid Tumor Program

TSC-100
Pre-clinical

Solid Tumor Program

TSC-200
Discovery

Long-term Vision

Leveraging our disruptive new technology platform that enables us to rapidly discover new targets and new TCRs directly from patients, we are building a growing collection of therapeutically active TCRs with diverse anti-tumor targets. Ultimately, this repository will be used to provide customized therapies for diverse groups of patients based on their specific tumor and HLA type.

Because life-changing therapies should be for everyone.

TCR Repository